person · Reporting owner

GIANAKAKOS ANASTASIOS

Disclosed activity across 3 companies

Tapewire entity: 36315
SEC CIK: 0001413822

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Kardigan, Inc.KARD · Entity 4569	Director · President & CEO	June 17, 2026	June 22, 2026
LianBioLIAN · Entity 9881	Director	February 15, 2024	February 20, 2024

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Kardigan, Inc.

Report date June 17, 2026 · Filed June 22, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectBy AEG 2021 Trust	5,665,090	Reported balance After 2026-06-17 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2026-06-17 · Conversion · Acquired 28,702 · Balance 5,665,090 F1: Each share of Series A Preferred Stock and Series B Preferred Stock (together the "Preferred Stock") was convertible into Common Stock on a 1.5928 for 1 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 upon the effectiveness of the Issuer's registration statement on Form S-1 relating to its initial public offering on June 17, 2026 and without payment of consideration. The Preferred Stock had no expiration date. F2: Represents shares held by AEG 2021 Trust. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose.
Common StockSEC Table I · non-derivative	IndirectBy KCM 2023 Trust	2,422,520	Reported balance After 2026-06-17 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2026-06-17 · Conversion · Acquired 41,001 · Balance 2,422,520 F1: Each share of Series A Preferred Stock and Series B Preferred Stock (together the "Preferred Stock") was convertible into Common Stock on a 1.5928 for 1 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 upon the effectiveness of the Issuer's registration statement on Form S-1 relating to its initial public offering on June 17, 2026 and without payment of consideration. The Preferred Stock had no expiration date. F3: Represents shares held by KCM 2023 Trust. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Exchange Act, except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose.
Common StockSEC Table I · non-derivative	IndirectBy spouse	498,692	Reported balance After 2026-06-17 transaction · row 3 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 3 · 2026-06-17 · Conversion · Acquired 498,692 · Balance 498,692 F1: Each share of Series A Preferred Stock and Series B Preferred Stock (together the "Preferred Stock") was convertible into Common Stock on a 1.5928 for 1 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 upon the effectiveness of the Issuer's registration statement on Form S-1 relating to its initial public offering on June 17, 2026 and without payment of consideration. The Preferred Stock had no expiration date. F4: The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Exchange Act, except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose.
Series A Preferred StockSEC Table II · derivative / convertible security	IndirectBy AEG 2021 Trust	0	Reported balance After 2026-06-17 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2026-06-17 · Conversion · Disposed 18,020 · Balance 0 F1: Each share of Series A Preferred Stock and Series B Preferred Stock (together the "Preferred Stock") was convertible into Common Stock on a 1.5928 for 1 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 upon the effectiveness of the Issuer's registration statement on Form S-1 relating to its initial public offering on June 17, 2026 and without payment of consideration. The Preferred Stock had no expiration date. F2: Represents shares held by AEG 2021 Trust. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose.
Series A Preferred StockSEC Table II · derivative / convertible security	IndirectBy KCM 2023 Trust	0	Reported balance After 2026-06-17 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2026-06-17 · Conversion · Disposed 25,742 · Balance 0 F1: Each share of Series A Preferred Stock and Series B Preferred Stock (together the "Preferred Stock") was convertible into Common Stock on a 1.5928 for 1 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 upon the effectiveness of the Issuer's registration statement on Form S-1 relating to its initial public offering on June 17, 2026 and without payment of consideration. The Preferred Stock had no expiration date. F3: Represents shares held by KCM 2023 Trust. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Exchange Act, except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose.
Series B Preferred StockSEC Table II · derivative / convertible security	IndirectBy spouse	0	Reported balance After 2026-06-17 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2026-06-17 · Conversion · Disposed 313,092 · Balance 0 F1: Each share of Series A Preferred Stock and Series B Preferred Stock (together the "Preferred Stock") was convertible into Common Stock on a 1.5928 for 1 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 upon the effectiveness of the Issuer's registration statement on Form S-1 relating to its initial public offering on June 17, 2026 and without payment of consideration. The Preferred Stock had no expiration date. F4: The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Exchange Act, except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose.
Common StockSEC Table I · non-derivative	Direct	49,821	Reported balance Holding disclosure · report date 2026-06-17 · row 4 Holding and transaction disclosures are not merged. 1 source row Row 4 · Balance 49,821
Common StockSEC Table I · non-derivative	IndirectBy Katina Mandas 2024 Qualified Annuity Trust dated April 29, 2024	4,778	Reported balance Holding disclosure · report date 2026-06-17 · row 5 Holding and transaction disclosures are not merged. 1 source row Row 5 · Balance 4,778 F5: Represents shares held by Katina Mandas 2024 Qualified Annuity Trust dated April 29, 2024. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Exchange Act, except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose.
Common StockSEC Table I · non-derivative	IndirectBy MJA Legacy Trust dated May 6, 2020	1,165,732	Reported balance Holding disclosure · report date 2026-06-17 · row 6 Holding and transaction disclosures are not merged. 1 source row Row 6 · Balance 1,165,732 F6: Represents shares held by MJA Legacy Trust dated May 6, 2020. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Exchange Act, except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose.

Filing footnotes · ownership attribution and instrument terms

F1: Each share of Series A Preferred Stock and Series B Preferred Stock (together the "Preferred Stock") was convertible into Common Stock on a 1.5928 for 1 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 upon the effectiveness of the Issuer's registration statement on Form S-1 relating to its initial public offering on June 17, 2026 and without payment of consideration. The Preferred Stock had no expiration date.

F2: Represents shares held by AEG 2021 Trust. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose.

F3: Represents shares held by KCM 2023 Trust. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Exchange Act, except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose.

F4: The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Exchange Act, except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose.

F5: Represents shares held by Katina Mandas 2024 Qualified Annuity Trust dated April 29, 2024. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Exchange Act, except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose.

F6: Represents shares held by MJA Legacy Trust dated May 6, 2020. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Exchange Act, except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose.

LianBio

Report date February 15, 2024 · Filed February 20, 2024

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Ordinary SharesSEC Table I · non-derivative	Direct	53,630	Ending reported balance After 2024-02-15 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2024-02-15 · Exercise / conversion · Acquired 36,300 · Balance 72,848 Row 2 · 2024-02-15 · Tax withholding · Disposed 19,218 · Balance 53,630
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.52 · Expires 2032-06-23	Direct	0	Reported balance After 2024-02-15 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2024-02-15 · Exercise / conversion · Disposed 36,300 · Balance 0 F1: The shares underlying the option became exercisable in full on June 23, 2023.
Ordinary SharesSEC Table I · non-derivative	IndirectBy Trust	309,623	Reported balance Holding disclosure · report date 2024-02-15 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 309,623

Filing footnotes · ownership attribution and instrument terms

F1: The shares underlying the option became exercisable in full on June 23, 2023.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

MyoKardia, Inc.

Report date November 17, 2020 · Filed November 20, 2020

Section 16 reporting ended · disclosed 2020-11-20. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2020-11-17 transaction · row 1 1 source row Row 1 · 2020-11-17 · Other · Disposed 141,405 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 3, 2020, by and among the Issuer, Bristol-Myers Squibb Company ("Parent"), and Gotham Merger Sub Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 17, 2020 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $225.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes. F2: A portion of this amount consists of unvested restricted stock units ("RSUs"). Pursuant to the terms of the Merger Agreement, each Issuer RSU that was outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled at the Effective Time and automatically converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the Offer Price.
Common StockSEC Table I · non-derivative	IndirectBy Reporting Person's Trust 2	Reported balance After 2020-11-17 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2020-11-17 · Other · Disposed 129,407 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 3, 2020, by and among the Issuer, Bristol-Myers Squibb Company ("Parent"), and Gotham Merger Sub Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 17, 2020 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $225.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes.
Common StockSEC Table I · non-derivative	IndirectBy Reporting Person's Trust 4	Reported balance After 2020-11-17 transaction · row 3 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 3 · 2020-11-17 · Other · Disposed 300,000 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 3, 2020, by and among the Issuer, Bristol-Myers Squibb Company ("Parent"), and Gotham Merger Sub Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 17, 2020 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $225.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes.
Common StockSEC Table I · non-derivative	IndirectBy Reporting Person's Trust 5	Reported balance After 2020-11-17 transaction · row 4 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 4 · 2020-11-17 · Other · Disposed 7,000 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 3, 2020, by and among the Issuer, Bristol-Myers Squibb Company ("Parent"), and Gotham Merger Sub Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 17, 2020 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $225.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes.
Common StockSEC Table I · non-derivative	IndirectBy reporting Person's Trust 6	Reported balance After 2020-11-17 transaction · row 5 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 5 · 2020-11-17 · Other · Disposed 10,000 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 3, 2020, by and among the Issuer, Bristol-Myers Squibb Company ("Parent"), and Gotham Merger Sub Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 17, 2020 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $225.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes.
Common StockSEC Table I · non-derivative	IndirectBy Trust 1	Reported balance After 2020-11-17 transaction · row 6 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 6 · 2020-11-17 · Other · Disposed 53,087 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 3, 2020, by and among the Issuer, Bristol-Myers Squibb Company ("Parent"), and Gotham Merger Sub Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 17, 2020 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $225.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes.
Common StockSEC Table I · non-derivative	IndirectBy Trust 2	Reported balance After 2020-11-17 transaction · row 7 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 7 · 2020-11-17 · Other · Disposed 53,087 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 3, 2020, by and among the Issuer, Bristol-Myers Squibb Company ("Parent"), and Gotham Merger Sub Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 17, 2020 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $225.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes.
Common StockSEC Table I · non-derivative	IndirectBy Trust 3	Reported balance After 2020-11-17 transaction · row 8 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 8 · 2020-11-17 · Other · Disposed 53,087 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 3, 2020, by and among the Issuer, Bristol-Myers Squibb Company ("Parent"), and Gotham Merger Sub Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 17, 2020 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $225.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes.
Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.51	Direct	Reported balance After 2020-11-17 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2020-11-17 · Disposition to issuer · Disposed 149,517 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option.
Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.08	Direct	Reported balance After 2020-11-17 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2020-11-17 · Disposition to issuer · Disposed 72,562 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option.
Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.25	Direct	Reported balance After 2020-11-17 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2020-11-17 · Disposition to issuer · Disposed 303,500 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option.
Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $52.00	Direct	Reported balance After 2020-11-17 transaction · row 12 Instrument identity requires review; Table II rows are not merged. 1 source row Row 12 · 2020-11-17 · Disposition to issuer · Disposed 184,100 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option.
Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $40.11	Direct	Reported balance After 2020-11-17 transaction · row 13 Instrument identity requires review; Table II rows are not merged. 1 source row Row 13 · 2020-11-17 · Disposition to issuer · Disposed 236,500 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option.
Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $70.40	Direct	Reported balance After 2020-11-17 transaction · row 14 Instrument identity requires review; Table II rows are not merged. 1 source row Row 14 · 2020-11-17 · Disposition to issuer · Disposed 142,733 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 3, 2020, by and among the Issuer, Bristol-Myers Squibb Company ("Parent"), and Gotham Merger Sub Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 17, 2020 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $225.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes.

F2: A portion of this amount consists of unvested restricted stock units ("RSUs"). Pursuant to the terms of the Merger Agreement, each Issuer RSU that was outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled at the Effective Time and automatically converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the Offer Price.

F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
April 16, 2020 Filed Apr 20, 2020 22:10 UTC	MyoKardia, Inc. MYOK · Entity 145206	SaleCommon Stock	1,000	$55.00	$55,000.00	Disclosure SEC source: 0000899243-20-011019 · doc4.xml · nonDerivative · entry 1 GIANAKAKOS ANASTASIOS · CIK 0001413822 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,796 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document
April 08, 2020 Filed Apr 10, 2020 22:27 UTC	MyoKardia, Inc. MYOK · Entity 145206	SaleCommon Stock	1,500	$50.00	$75,000.00	Disclosure SEC source: 0000899243-20-010647 · doc4.xml · nonDerivative · entry 1 GIANAKAKOS ANASTASIOS · CIK 0001413822 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,796 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document
April 02, 2020 Filed Apr 6, 2020 20:06 UTC	MyoKardia, Inc. MYOK · Entity 145206	SaleCommon Stock	600	$46.23	$27,736.02	Disclosure SEC source: 0000899243-20-010312 · doc4.xml · nonDerivative · entry 4 GIANAKAKOS ANASTASIOS · CIK 0001413822 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,296 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F5 · price: Represents the weighted average sale price of the shares sold ranging from $46.03 to $46.54 per share. Read SEC document
April 02, 2020 Filed Apr 6, 2020 20:06 UTC	MyoKardia, Inc. MYOK · Entity 145206	SaleCommon Stock	300	$45.35	$13,605.00	Disclosure SEC source: 0000899243-20-010312 · doc4.xml · nonDerivative · entry 3 GIANAKAKOS ANASTASIOS · CIK 0001413822 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,896 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F4 · price: Represents the weighted average sale price of the shares sold ranging from $45.02 to $45.83 per share. Read SEC document
April 02, 2020 Filed Apr 6, 2020 20:06 UTC	MyoKardia, Inc. MYOK · Entity 145206	SaleCommon Stock	1,000	$44.47	$44,469.00	Disclosure SEC source: 0000899243-20-010312 · doc4.xml · nonDerivative · entry 2 GIANAKAKOS ANASTASIOS · CIK 0001413822 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,196 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: Represents the weighted average sale price of the shares sold ranging from $43.99 to $44.97 per share. Read SEC document
April 02, 2020 Filed Apr 6, 2020 20:06 UTC	MyoKardia, Inc. MYOK · Entity 145206	SaleCommon Stock	600	$43.51	$26,107.02	Disclosure SEC source: 0000899243-20-010312 · doc4.xml · nonDerivative · entry 1 GIANAKAKOS ANASTASIOS · CIK 0001413822 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,196 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: Represents the weighted average sale price of the shares sold ranging from $42.91 to $43.89 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the ranges reported in footnotes 2 through 5. Read SEC document
March 02, 2020 Filed Mar 4, 2020 22:42 UTC	MyoKardia, Inc. MYOK · Entity 145206	SaleCommon Stock	22	$65.97	$1,451.34	Disclosure SEC source: 0000899243-20-006984 · doc4.xml · nonDerivative · entry 4 GIANAKAKOS ANASTASIOS · CIK 0001413822 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,796 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document
March 02, 2020 Filed Mar 4, 2020 22:42 UTC	MyoKardia, Inc. MYOK · Entity 145206	SaleCommon Stock	1,800	$65.19	$117,345.60	Disclosure SEC source: 0000899243-20-006984 · doc4.xml · nonDerivative · entry 3 GIANAKAKOS ANASTASIOS · CIK 0001413822 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,818 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F4 · price: Represents the weighted average sale price of the shares sold ranging from $64.89 to $65.82 per share. Read SEC document
March 02, 2020 Filed Mar 4, 2020 22:42 UTC	MyoKardia, Inc. MYOK · Entity 145206	SaleCommon Stock	2,070	$64.35	$133,202.84	Disclosure SEC source: 0000899243-20-006984 · doc4.xml · nonDerivative · entry 2 GIANAKAKOS ANASTASIOS · CIK 0001413822 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,618 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: Represents the weighted average sale price of the shares sold ranging from $63.80 to $64.74 per share. Read SEC document
March 02, 2020 Filed Mar 4, 2020 22:42 UTC	MyoKardia, Inc. MYOK · Entity 145206	SaleCommon Stock	1,108	$63.40	$70,246.42	Disclosure SEC source: 0000899243-20-006984 · doc4.xml · nonDerivative · entry 1 GIANAKAKOS ANASTASIOS · CIK 0001413822 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,688 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: Represents the weighted average sale price of the shares sold ranging from $62.77 to $63.76 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the ranges reported in footnotes 2 through 4. Read SEC document
February 14, 2020 Filed Feb 20, 2020 01:44 UTC	MyoKardia, Inc. MYOK · Entity 145206	GrantRestricted Stock Units · Derivative	46,083	$0.00	$0.00	Disclosure SEC source: 0000899243-20-005189 · doc4.xml · derivative · entry 2 GIANAKAKOS ANASTASIOS · CIK 0001413822 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,083 Underlying: Common Stock · 46,083 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in equal annual installments over 4 years from January 1, 2020, so that all of the underlying shares shall be vested on January 1, 2024, subject to the Reporting Person's continued employment with the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause after a change of control of the Issuer. F2 · derivative.exercise_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in equal annual installments over 4 years from January 1, 2020, so that all of the underlying shares shall be vested on January 1, 2024, subject to the Reporting Person's continued employment with the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause after a change of control of the Issuer. F2 · derivative.expiration_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in equal annual installments over 4 years from January 1, 2020, so that all of the underlying shares shall be vested on January 1, 2024, subject to the Reporting Person's continued employment with the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause after a change of control of the Issuer. Read SEC document
February 14, 2020 Filed Feb 20, 2020 01:44 UTC	MyoKardia, Inc. MYOK · Entity 145206	GrantStock Option (Right to Buy) · Derivative	142,733	$0.00 Strike: $70.40	$0.00	Disclosure SEC source: 0000899243-20-005189 · doc4.xml · derivative · entry 1 GIANAKAKOS ANASTASIOS · CIK 0001413822 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,733 Underlying: Common Stock · 142,733 shares Expires 2030-02-13 F1 · derivative.exercise_date: The shares underlying the option vest in 48 equal monthly installments from January 1, 2020, so long as the Reporting Person continues to be an employee of the Issuer through each vesting date. This option is subject to accelerated vesting upon termination without cause upon a change of control of the Issuer. Read SEC document
February 03, 2020 Filed Feb 6, 2020 01:22 UTC	MyoKardia, Inc. MYOK · Entity 145206	SaleCommon Stock	1,000	$69.74	$69,744.00	Disclosure SEC source: 0000899243-20-003410 · doc4.xml · nonDerivative · entry 2 GIANAKAKOS ANASTASIOS · CIK 0001413822 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,777 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: Represents the weighted average sale price of the shares sold ranging from $69.57 to $69.94 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document
February 03, 2020 Filed Feb 6, 2020 01:22 UTC	MyoKardia, Inc. MYOK · Entity 145206	SaleCommon Stock	4,000	$69.27	$277,076.80	Disclosure SEC source: 0000899243-20-003410 · doc4.xml · nonDerivative · entry 1 GIANAKAKOS ANASTASIOS · CIK 0001413822 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,777 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: Represents the weighted average sale price of the shares sold ranging from $68.55 to $69.54 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document
January 14, 2020 Filed Jan 15, 2020 01:26 UTC	MyoKardia, Inc. MYOK · Entity 145206	SaleCommon Stock	5,000	$75.39	$376,964.50	Disclosure SEC source: 0000899243-20-001197 · doc4.xml · nonDerivative · entry 1 GIANAKAKOS ANASTASIOS · CIK 0001413822 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,777 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: Represents the weighted average sale price of the shares sold ranging from $75.00 to $75.68 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document
January 06, 2020 Filed Jan 8, 2020 00:39 UTC	MyoKardia, Inc. MYOK · Entity 145206	SaleCommon Stock	12,687	$68.45	$868,439.11	Disclosure SEC source: 0000899243-20-000793 · doc4.xml · nonDerivative · entry 1 GIANAKAKOS ANASTASIOS · CIK 0001413822 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,777 F1 · kind: Shares sold to cover withholding taxes in connection with vesting of Restricted Stock Units reported on Form 4 filed by the Reporting Person on January 3, 2020. F2 · price: Represents the weighted average sale price of the shares sold ranging from $68.35 to $68.66 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document
January 03, 2020 Filed Jan 4, 2020 01:18 UTC	MyoKardia, Inc. MYOK · Entity 145206	SaleCommon Stock	2,084	$72.27	$150,616.52	Disclosure SEC source: 0000899243-20-000387 · doc4.xml · nonDerivative · entry 4 GIANAKAKOS ANASTASIOS · CIK 0001413822 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,464 F4 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F7 · price: Represents the weighted average sale price of the shares sold ranging from $72.03 to $72.73 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document
January 03, 2020 Filed Jan 4, 2020 01:18 UTC	MyoKardia, Inc. MYOK · Entity 145206	SaleCommon Stock	2,616	$71.59	$187,286.50	Disclosure SEC source: 0000899243-20-000387 · doc4.xml · nonDerivative · entry 3 GIANAKAKOS ANASTASIOS · CIK 0001413822 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,548 F4 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F6 · price: Represents the weighted average sale price of the shares sold ranging from $70.99 to $71.98 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document
January 03, 2020 Filed Jan 4, 2020 01:18 UTC	MyoKardia, Inc. MYOK · Entity 145206	SaleCommon Stock	300	$70.35	$21,105.00	Disclosure SEC source: 0000899243-20-000387 · doc4.xml · nonDerivative · entry 2 GIANAKAKOS ANASTASIOS · CIK 0001413822 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,164 F4 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F5 · price: Represents the weighted average sale price of the shares sold ranging from $69.93 to $70.56 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document
January 01, 2020 Filed Jan 4, 2020 01:18 UTC	MyoKardia, Inc. MYOK · Entity 145206	Exercise / conversionRestricted Stock Units · Derivative	20,300	$0.00	$0.00	Disclosure SEC source: 0000899243-20-000387 · doc4.xml · derivative · entry 11 GIANAKAKOS ANASTASIOS · CIK 0001413822 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,900 Underlying: Common Stock · 20,300 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in equal annual installments over 4 years from January 1, 2019, so that all of the underlying shares shall be vested on January 1, 2023, subject to the Reporting Person's continued employment with the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause after a change of control of the Issuer. F3 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in equal annual installments over 4 years from January 1, 2019, so that all of the underlying shares shall be vested on January 1, 2023, subject to the Reporting Person's continued employment with the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause after a change of control of the Issuer. Read SEC document
January 01, 2020 Filed Jan 4, 2020 01:18 UTC	MyoKardia, Inc. MYOK · Entity 145206	Exercise / conversionRestricted Stock Units · Derivative	7,650	$0.00	$0.00	Disclosure SEC source: 0000899243-20-000387 · doc4.xml · derivative · entry 10 GIANAKAKOS ANASTASIOS · CIK 0001413822 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,300 Underlying: Common Stock · 7,650 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in equal annual installments over 4 years from January 1, 2018, so that all of the underlying shares shall be vested on January 1, 2022, subject to the Reporting Person's continued employment with the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause after a change of control of the Issuer. F2 · derivative.expiration_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in equal annual installments over 4 years from January 1, 2018, so that all of the underlying shares shall be vested on January 1, 2022, subject to the Reporting Person's continued employment with the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause after a change of control of the Issuer. Read SEC document
January 01, 2020 Filed Jan 4, 2020 01:18 UTC	MyoKardia, Inc. MYOK · Entity 145206	Exercise / conversionCommon Stock	27,950	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-20-000387 · doc4.xml · nonDerivative · entry 1 GIANAKAKOS ANASTASIOS · CIK 0001413822 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,464 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document
December 02, 2019 Filed Dec 4, 2019 21:26 UTC	MyoKardia, Inc. MYOK · Entity 145206	SaleCommon Stock	4,350	$65.14	$283,342.47	Disclosure SEC source: 0000899243-19-028482 · doc4.xml · nonDerivative · entry 2 GIANAKAKOS ANASTASIOS · CIK 0001413822 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,514 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: Represents the weighted average sale price of the shares sold ranging from $64.66 to $65.65 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document
December 02, 2019 Filed Dec 4, 2019 21:26 UTC	MyoKardia, Inc. MYOK · Entity 145206	SaleCommon Stock	650	$64.24	$41,755.48	Disclosure SEC source: 0000899243-19-028482 · doc4.xml · nonDerivative · entry 1 GIANAKAKOS ANASTASIOS · CIK 0001413822 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,864 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: Represents the weighted average sale price of the shares sold ranging from $63.66 to $64.58 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document
November 04, 2019 Filed Nov 6, 2019 23:33 UTC	MyoKardia, Inc. MYOK · Entity 145206	SaleCommon Stock	5,000	$59.07	$295,364.50	Disclosure SEC source: 0000899243-19-026831 · doc4.xml · nonDerivative · entry 2 GIANAKAKOS ANASTASIOS · CIK 0001413822 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,514 F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: Represents the weighted average sale price of the shares sold ranging from $58.71 to $59.47 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document
October 31, 2019 Filed Nov 6, 2019 23:33 UTC	MyoKardia, Inc. MYOK · Entity 145206	GrantCommon Stock	44	$40.07	$1,763.04	Disclosure SEC source: 0000899243-19-026831 · doc4.xml · nonDerivative · entry 1 GIANAKAKOS ANASTASIOS · CIK 0001413822 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,514 F1 · kind: Shares acquired pursuant to the Issuer's 2013 Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3(c). Read SEC document
October 03, 2019 Filed Oct 4, 2019 21:27 UTC	MyoKardia, Inc. MYOK · Entity 145206	SaleCommon Stock	1,000	$55.00	$55,000.00	Disclosure SEC source: 0000899243-19-025124 · doc4.xml · nonDerivative · entry 4 GIANAKAKOS ANASTASIOS · CIK 0001413822 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,470 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document
October 02, 2019 Filed Oct 4, 2019 21:27 UTC	MyoKardia, Inc. MYOK · Entity 145206	SaleCommon Stock	758	$53.10	$40,247.75	Disclosure SEC source: 0000899243-19-025124 · doc4.xml · nonDerivative · entry 3 GIANAKAKOS ANASTASIOS · CIK 0001413822 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,470 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document
October 02, 2019 Filed Oct 4, 2019 21:27 UTC	MyoKardia, Inc. MYOK · Entity 145206	SaleCommon Stock	2,542	$52.29	$132,933.13	Disclosure SEC source: 0000899243-19-025124 · doc4.xml · nonDerivative · entry 2 GIANAKAKOS ANASTASIOS · CIK 0001413822 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,228 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document
October 02, 2019 Filed Oct 4, 2019 21:27 UTC	MyoKardia, Inc. MYOK · Entity 145206	SaleCommon Stock	700	$51.33	$35,930.02	Disclosure SEC source: 0000899243-19-025124 · doc4.xml · nonDerivative · entry 1 GIANAKAKOS ANASTASIOS · CIK 0001413822 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,770 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document
September 11, 2019 Filed Sep 12, 2019 20:16 UTC	MyoKardia, Inc. MYOK · Entity 145206	SaleCommon Stock	1,000	$55.00	$55,000.00	Disclosure SEC source: 0000899243-19-023423 · doc4.xml · nonDerivative · entry 1 GIANAKAKOS ANASTASIOS · CIK 0001413822 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,470 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document
September 03, 2019 Filed Sep 5, 2019 20:05 UTC	MyoKardia, Inc. MYOK · Entity 145206	SaleCommon Stock	1,100	$54.09	$59,499.99	Disclosure SEC source: 0000899243-19-022824 · doc4.xml · nonDerivative · entry 3 GIANAKAKOS ANASTASIOS · CIK 0001413822 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,470 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F4 · price: Represents the weighted average sale price of the shares sold ranging from $53.56 to $54.36. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document
September 03, 2019 Filed Sep 5, 2019 20:05 UTC	MyoKardia, Inc. MYOK · Entity 145206	SaleCommon Stock	1,000	$52.75	$52,750.00	Disclosure SEC source: 0000899243-19-022824 · doc4.xml · nonDerivative · entry 2 GIANAKAKOS ANASTASIOS · CIK 0001413822 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,570 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: Represents the weighted average sale price of the shares sold ranging from $52.11 to $53.05. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document
September 03, 2019 Filed Sep 5, 2019 20:05 UTC	MyoKardia, Inc. MYOK · Entity 145206	SaleCommon Stock	1,900	$50.70	$96,334.75	Disclosure SEC source: 0000899243-19-022824 · doc4.xml · nonDerivative · entry 1 GIANAKAKOS ANASTASIOS · CIK 0001413822 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,570 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: Represents the weighted average sale price of the shares sold ranging from $50.44 to $51.26 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document
August 08, 2019 Filed Aug 9, 2019 21:11 UTC	MyoKardia, Inc. MYOK · Entity 145206	SaleCommon Stock	1,000	$55.09	$55,090.00	Disclosure SEC source: 0000899243-19-021467 · doc4.xml · nonDerivative · entry 1 GIANAKAKOS ANASTASIOS · CIK 0001413822 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,470 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document
August 02, 2019 Filed Aug 5, 2019 20:05 UTC	MyoKardia, Inc. MYOK · Entity 145206	SaleCommon Stock	200	$53.82	$10,763.50	Disclosure SEC source: 0000899243-19-020987 · doc4.xml · nonDerivative · entry 2 GIANAKAKOS ANASTASIOS · CIK 0001413822 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,470 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: Represents the weighted average sale price of the shares sold ranging from $53.77 to $53.86 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document
August 02, 2019 Filed Aug 5, 2019 20:05 UTC	MyoKardia, Inc. MYOK · Entity 145206	SaleCommon Stock	3,800	$53.20	$202,171.40	Disclosure SEC source: 0000899243-19-020987 · doc4.xml · nonDerivative · entry 1 GIANAKAKOS ANASTASIOS · CIK 0001413822 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,670 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: Represents the weighted average sale price of the shares sold ranging from $52.72 to $53.63 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document
July 22, 2019 Filed Jul 23, 2019 20:05 UTC	MyoKardia, Inc. MYOK · Entity 145206	SaleCommon Stock	1,000	$55.00	$55,000.00	Disclosure SEC source: 0000899243-19-020095 · doc4.xml · nonDerivative · entry 1 GIANAKAKOS ANASTASIOS · CIK 0001413822 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,470 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document
July 05, 2019 Filed Jul 8, 2019 21:35 UTC	MyoKardia, Inc. MYOK · Entity 145206	SaleCommon Stock	2,450	$50.10	$122,751.86	Disclosure SEC source: 0000899243-19-019317 · doc4.xml · nonDerivative · entry 4 GIANAKAKOS ANASTASIOS · CIK 0001413822 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,470 F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F4 · price: Represents the weighted average sale price of the shares sold ranging from $49.82 to $50.49 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document
July 05, 2019 Filed Jul 8, 2019 21:35 UTC	MyoKardia, Inc. MYOK · Entity 145206	SaleCommon Stock	1,550	$49.13	$76,151.19	Disclosure SEC source: 0000899243-19-019317 · doc4.xml · nonDerivative · entry 3 GIANAKAKOS ANASTASIOS · CIK 0001413822 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,920 F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: Represents the weighted average sale price of the shares sold ranging from $48.68 to $49.59 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document
June 18, 2019 Filed Jul 8, 2019 21:35 UTC	MyoKardia, Inc. MYOK · Entity 145206	GiftCommon Stock	39,000	$0.00	$0.00	Disclosure SEC source: 0000899243-19-019317 · doc4.xml · nonDerivative · entry 2 GIANAKAKOS ANASTASIOS · CIK 0001413822 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Reporting Person's Trust 2 Disclosed balance after: 49,473 F1 · kind: Transfer of shares to Reporting Person from Reporting Person's Trust 2. Read SEC document
June 18, 2019 Filed Jul 8, 2019 21:35 UTC	MyoKardia, Inc. MYOK · Entity 145206	GiftCommon Stock	39,000	$0.00	$0.00	Disclosure SEC source: 0000899243-19-019317 · doc4.xml · nonDerivative · entry 1 GIANAKAKOS ANASTASIOS · CIK 0001413822 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,470 F1 · kind: Transfer of shares to Reporting Person from Reporting Person's Trust 2. Read SEC document
April 30, 2019 Filed Jun 3, 2019 21:48 UTC	MyoKardia, Inc. MYOK · Entity 145206	GrantCommon Stock	503	$40.78	$20,513.85	Disclosure SEC source: 0000899243-19-015395 · doc4.xml · nonDerivative · entry 1 GIANAKAKOS ANASTASIOS · CIK 0001413822 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,470 F1 · kind: Shares acquired pursuant to the Issuer's 2013 Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3(c). Read SEC document
February 08, 2019 Filed Feb 12, 2019 21:23 UTC	MyoKardia, Inc. MYOK · Entity 145206	GrantRestricted Stock Units · Derivative	81,200	$0.00	$0.00	Disclosure SEC source: 0000899243-19-003283 · doc4.xml · derivative · entry 2 GIANAKAKOS ANASTASIOS · CIK 0001413822 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,200 Underlying: Common Stock · 81,200 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in equal annual installments over 4 years from January 1, 2019, so that all of the underlying shares shall be vested on January 1, 2023, subject to the Reporting Person's continued employment with the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause after a change of control of the Issuer. F2 · derivative.exercise_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in equal annual installments over 4 years from January 1, 2019, so that all of the underlying shares shall be vested on January 1, 2023, subject to the Reporting Person's continued employment with the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause after a change of control of the Issuer. F2 · derivative.expiration_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in equal annual installments over 4 years from January 1, 2019, so that all of the underlying shares shall be vested on January 1, 2023, subject to the Reporting Person's continued employment with the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause after a change of control of the Issuer. Read SEC document
February 08, 2019 Filed Feb 12, 2019 21:23 UTC	MyoKardia, Inc. MYOK · Entity 145206	GrantStock Option (Right to Buy) · Derivative	236,500	$0.00 Strike: $40.11	$0.00	Disclosure SEC source: 0000899243-19-003283 · doc4.xml · derivative · entry 1 GIANAKAKOS ANASTASIOS · CIK 0001413822 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 236,500 Underlying: Common Stock · 236,500 shares Expires 2029-02-07 F1 · derivative.exercise_date: The shares underlying the option vest in 48 equal monthly installments from January 1, 2019, so long as the Reporting Person continues to be an employee of the Issuer through each vesting date. This option is subject to accelerated vesting upon termination without cause upon a change of control of the Issuer. Read SEC document
January 07, 2019 Filed Jan 12, 2019 01:18 UTC	MyoKardia, Inc. MYOK · Entity 145206	SaleCommon Stock	2,770	$44.11	$122,197.44	Disclosure SEC source: 0000899243-19-001073 · doc4.xml · nonDerivative · entry 1 GIANAKAKOS ANASTASIOS · CIK 0001413822 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,967 F1 · kind: Shares sold to cover withholding taxes in connection with vesting of Restricted Stock Units reported on Form 4 filed by the Reporting Person on January 3, 2019. Read SEC document
January 04, 2019 Filed Jan 9, 2019 00:12 UTC	MyoKardia, Inc. MYOK · Entity 145206	PurchaseCommon Stock	1,600	$39.87	$63,795.52	Disclosure SEC source: 0000899243-19-000799 · doc4.xml · nonDerivative · entry 2 GIANAKAKOS ANASTASIOS · CIK 0001413822 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Reporting Person's Trust 2 Disclosed balance after: 88,473 F1 · kind: These shares were acquired through an open market purchase. Read SEC document
January 04, 2019 Filed Jan 9, 2019 00:12 UTC	MyoKardia, Inc. MYOK · Entity 145206	PurchaseCommon Stock	900	$39.84	$35,851.50	Disclosure SEC source: 0000899243-19-000799 · doc4.xml · nonDerivative · entry 1 GIANAKAKOS ANASTASIOS · CIK 0001413822 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Reporting Person's Trust 2 Disclosed balance after: 86,873 F1 · kind: These shares were acquired through an open market purchase. Read SEC document
January 01, 2019 Filed Jan 4, 2019 02:36 UTC	MyoKardia, Inc. MYOK · Entity 145206	Exercise / conversionRestricted Stock Units · Derivative	7,650	$0.00	$0.00	Disclosure SEC source: 0000899243-19-000370 · doc4.xml · derivative · entry 7 GIANAKAKOS ANASTASIOS · CIK 0001413822 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,950 Underlying: Common Stock · 7,650 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in equal annual installments over 4 years from January 1, 2018, so that all of the underlying shares shall be vested on January 1, 2022, subject to the Reporting Person's continued employment with the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause after a change of control of the Issuer. F2 · derivative.expiration_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in equal annual installments over 4 years from January 1, 2018, so that all of the underlying shares shall be vested on January 1, 2022, subject to the Reporting Person's continued employment with the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause after a change of control of the Issuer. Read SEC document
January 01, 2019 Filed Jan 4, 2019 02:36 UTC	MyoKardia, Inc. MYOK · Entity 145206	Exercise / conversionCommon Stock	7,650	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-19-000370 · doc4.xml · nonDerivative · entry 1 GIANAKAKOS ANASTASIOS · CIK 0001413822 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,737 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.